

Frank van Leth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5024566/publications.pdf>

Version: 2024-02-01

118
papers

4,402
citations

186265

28
h-index

114465

63
g-index

122
all docs

122
docs citations

122
times ranked

4729
citing authors

#	ARTICLE	IF	CITATIONS
1	Unbiased antimicrobial resistance prevalence estimates through population-based surveillance. <i>Clinical Microbiology and Infection</i> , 2023, 29, 429-433.	6.0	4
2	Clinical Reasoning Underlying Guideline Nonadherence in Urinary Tract Infections in Nursing Homes. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 896-898.	2.5	0
3	Incidence and factors associated with active tuberculosis among people living with HIV after long-term antiretroviral therapy in Thailand: a competing risk model. <i>BMC Infectious Diseases</i> , 2022, 22, 346.	2.9	3
4	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. <i>European Respiratory Journal</i> , 2022, 59, 2200388.	6.7	15
5	Sensitivity of C-Reactive Protein and Procalcitonin Measured by Point-of-Care Tests to Diagnose Urinary Tract Infections in Nursing Home Residents: A Cross-Sectional Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e3867-e3875.	5.8	10
6	Antimicrobial resistance among uropathogens in the Asia-Pacific region: a systematic review. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab003.	2.1	15
7	Defining Outcomes of Tuberculosis (Treatment): From the Past to the Future. <i>Respiration</i> , 2021, 100, 843-852.	2.6	8
8	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. <i>European Respiratory Journal</i> , 2021, 58, 2003492.	6.7	27
9	Pathogen-free diagnosis of tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1066.	9.1	0
10	The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of <i>Plasmodium vivax</i> infections: a randomized, controlled trial in Lao PDR. <i>Malaria Journal</i> , 2020, 19, 4.	2.3	4
11	Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. <i>Nature Medicine</i> , 2020, 26, 1941-1949.	30.7	58
12	Appropriateness of diagnosis and antibiotic use in sepsis patients admitted to a tertiary hospital in Indonesia. <i>Postgraduate Medicine</i> , 2020, 133, 1-6.	2.0	4
13	Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate <i>Plasmodium falciparum</i> have only a transient impact on <i>Plasmodium vivax</i> : Findings from randomised controlled trials. <i>PLoS ONE</i> , 2020, 15, e0228190.	2.5	6
14	Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia. <i>PLoS ONE</i> , 2020, 15, e0230489.	2.5	9
15	Title is missing!. , 2020, 15, e0230489.		0
16	Title is missing!. , 2020, 15, e0230489.		0
17	Title is missing!. , 2020, 15, e0230489.		0
18	Title is missing!. , 2020, 15, e0230489.		0

#	ARTICLE	IF	CITATIONS
19	Management of patients with multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 645-662.	1.2	55
20	Changes in disclosure, adherence and healthcare interactions after the introduction of immediate ART initiation: an analysis of patient experiences in Swaziland. <i>Tropical Medicine and International Health</i> , 2019, 24, 563-570.	2.3	7
21	Sensitivity of point-of-care testing C reactive protein and procalcitonin to diagnose urinary tract infections in Dutch nursing homes: PROGRESS study protocol. <i>BMJ Open</i> , 2019, 9, e031269.	1.9	14
22	Rethinking Antimicrobial Resistance Surveillance: A Role for Lot Quality Assurance Sampling. <i>American Journal of Epidemiology</i> , 2019, 188, 734-742.	3.4	12
23	The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. <i>European Respiratory Journal</i> , 2019, 53, 1802089.	6.7	9
24	Bridging the TB data gap: <i>in silico</i> extraction of rifampicin-resistant tuberculosis diagnostic test results from whole genome sequence data. <i>PeerJ</i> , 2019, 7, e7564.	2.0	4
25	Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 379-386.	5.6	27
26	Relapse-free cure from multidrug-resistant tuberculosis in Germany. <i>European Respiratory Journal</i> , 2018, 51, 1702122.	6.7	17
27	Time to revise WHO-recommended definitions of MDR-TB treatment outcomes. <i>Lancet Respiratory Medicine</i> , 2018, 6, 246-248.	10.7	11
28	Pharmacy-based hypertension care employing mHealth in Lagos, Nigeria – a mixed methods feasibility study. <i>BMC Health Services Research</i> , 2018, 18, 934.	2.2	33
29	Predictive value of the urinary dipstick test in the management of patients with urinary tract infection-associated symptoms in primary care in Indonesia: a cross-sectional study. <i>BMJ Open</i> , 2018, 8, e023051.	1.9	9
30	Treatment responses in multidrug-resistant tuberculosis in Germany. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 399-406.	1.2	8
31	Testing for LTBI: more of the same or a step forward?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 591-591.	1.2	1
32	Antimicrobial resistance in uropathogens and appropriateness of empirical treatment: a population-based surveillance study in Indonesia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw578.	3.0	27
33	Tuberculosis resistance-conferring mutations with fitness cost among HIV-positive individuals in Uganda. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 531-536.	1.2	8
34	Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. <i>Infectious Diseases</i> , 2017, 49, 161-169.	2.8	16
35	Treatment outcomes of MDR-TB and HIV co-infection in Europe. <i>European Respiratory Journal</i> , 2017, 49, 1602363.	6.7	17
36	Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1222-1224.	5.6	11

#	ARTICLE	IF	CITATIONS
37	Rapid assessment of antimicrobial resistance prevalence using a Lot Quality Assurance sampling approach. <i>Future Microbiology</i> , 2017, 12, 369-377.	2.0	5
38	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1489-1490.	5.6	2
39	An easy tool to assess ventilation in health facilities as part of air-borne transmission prevention: a cross-sectional survey from Uganda. <i>BMC Infectious Diseases</i> , 2017, 17, 325.	2.9	2
40	Prevalence of pulmonary tuberculosis in adult population of Tanzania: a national survey, 2012. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1014-1021.	1.2	29
41	Viral Load and Risk of Tuberculosis in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, e51-e53.	2.1	10
42	Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1029-1031.	5.6	71
43	Population impact of factors associated with prevalent pulmonary tuberculosis in Tanzania. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1326-1333.	1.2	8
44	Treatment Outcomes in Multidrug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2016, 375, 1103-1105.	27.0	73
45	Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1265-1271.	1.4	11
46	Intention of physicians to implement guidelines for screening and treatment of latent tuberculosis infection in HIV-infected patients in The Netherlands: a mixed-method design. <i>BMC Public Health</i> , 2016, 16, 915.	2.9	15
47	TB-HIV co-infection in the Netherlands: estimating prevalence and under-reporting in national registration databases using a capture-recapture analysis. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 556-560.	3.7	11
48	Health care-seeking behaviour among people with cough in Tanzania: findings from a tuberculosis prevalence survey. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 640-646.	1.2	30
49	Multidrug-Resistant Tuberculosis in Europe, 2010-2011. <i>Emerging Infectious Diseases</i> , 2015, 21, 409-416.	4.3	75
50	Numbers needed to treat to prevent tuberculosis. <i>European Respiratory Journal</i> , 2015, 46, 1836-1838.	6.7	28
51	Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. <i>European Respiratory Journal</i> , 2015, 45, 1081-1088.	6.7	44
52	Factors associated with poor knowledge among adults on tuberculosis in Bangladesh: results from a nationwide survey. <i>Journal of Health, Population and Nutrition</i> , 2015, 34, 2.	2.0	25
53	Implementation of tuberculosis infection prevention and control in Mozambican health care facilities. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 44-49.	1.2	20
54	Beyond multidrug-resistant tuberculosis in Europe: a TBNET study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1524-1527.	1.2	23

#	ARTICLE	IF	CITATIONS
55	Latent tuberculosis infection as a target for tuberculosis control. <i>Future Microbiology</i> , 2015, 10, 905-908.	2.0	2
56	Healthcare Workers' Challenges in the Implementation of Tuberculosis Infection Prevention and Control Measures in Mozambique. <i>PLoS ONE</i> , 2014, 9, e114364.	2.5	31
57	Care seeking in tuberculosis: results from a countrywide cluster randomised survey in Bangladesh. <i>BMJ Open</i> , 2014, 4, e004766.	1.9	12
58	Antiretroviral therapy and tuberculosis: does the regimen matter?. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 5-7.	4.4	0
59	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2014, 44, 23-63.	6.7	256
60	Design of pragmatic trials of tuberculosis interventions. <i>Lancet, The</i> , 2014, 383, 213-214.	13.7	3
61	Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1168-1176.	5.6	196
62	Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2337-2353.	3.0	143
63	Embracing the challenges of HIV-TB co-infection in children [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 379-379.	1.2	4
64	Validation of indirect tuberculosis treatment adherence measures in a resource-constrained setting. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 804-809.	1.2	5
65	Health workers' performance in the implementation of Patient Centred Tuberculosis Treatment (PCT) strategy under programmatic conditions in Tanzania: a cross sectional study. <i>BMC Health Services Research</i> , 2013, 13, 101.	2.2	6
66	Comparison of direct versus concentrated smear microscopy in detection of pulmonary tuberculosis. <i>BMC Research Notes</i> , 2013, 6, 291.	1.4	36
67	Are routine tuberculosis programme data suitable to report on antiretroviral therapy use of HIV-infected tuberculosis patients?. <i>BMC Research Notes</i> , 2013, 6, 23.	1.4	5
68	TB diagnostic process management of patients in a referral hospital in Mozambique in comparison with the 2007 WHO recommendations for the diagnosis of smear-negative pulmonary TB and extrapulmonary TB. <i>International Health</i> , 2013, 5, 302-308.	2.0	16
69	Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting. <i>Antiviral Therapy</i> , 2013, 18, 615-622.	1.0	3
70	Tuberculin survey in Bangladesh, 2007-2009: prevalence of tuberculous infection and implications for TB control. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 1267-1272.	1.2	12
71	Predictive Value of the Tuberculin Skin Test among Newly Arriving Immigrants. <i>PLoS ONE</i> , 2013, 8, e60130.	2.5	10
72	Epidemiology of Tuberculosis in an Urban Slum of Dhaka City, Bangladesh. <i>PLoS ONE</i> , 2013, 8, e77721.	2.5	47

#	ARTICLE	IF	CITATIONS
73	Epidemiological Surveys Embedded in Technical Assistance to Tuberculosis Control Programmes. The Open Infectious Diseases Journal, 2013, 7, 65-71.	0.6	1
74	Editorial - Technical Assistance to Tuberculosis Control Programmes as a Platform for Infectious Disease Research. The Open Infectious Diseases Journal, 2013, 7, 21-22.	0.6	0
75	Multidrug Resistance Among New Tuberculosis Cases. Epidemiology, 2012, 23, 293-300.	2.7	13
76	Role of the QuantiFERON®-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection. European Respiratory Journal, 2012, 40, 1443-1449.	6.7	32
77	Missed opportunities in tuberculosis control in The Netherlands due to prioritization of contact investigations. European Journal of Public Health, 2012, 22, 177-182.	0.3	12
78	Prevalence of smear-positive tuberculosis in persons aged ≥15 years in Bangladesh: results from a national survey, 2007–2009. Epidemiology and Infection, 2012, 140, 1018-1027.	2.1	26
79	Unrecognised tuberculosis at antiretroviral therapy initiation is associated with lower CD4+ T cell recovery. Tropical Medicine and International Health, 2012, 17, 1527-1533.	2.3	14
80	The effect of tuberculosis and antiretroviral treatment on CD4+ cell count response in HIV-positive tuberculosis patients in Mozambique. BMC Public Health, 2012, 12, 670.	2.9	2
81	Implementation and effect of intensified case finding on diagnosis of tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort study.. BMC Public Health, 2012, 12, 674.	2.9	13
82	Socio Economic Position in TB Prevalence and Access to Services: Results from a Population Prevalence Survey and a Facility-Based Survey in Bangladesh. PLoS ONE, 2012, 7, e44980.	2.5	32
83	Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study. HIV Medicine, 2012, 13, 337-344.	2.2	23
84	Adherence by Dutch Public Health Nurses to the National Guidelines for Tuberculosis Contact Investigation. PLoS ONE, 2012, 7, e49649.	2.5	9
85	Adherence to Tuberculosis Therapy among Patients Receiving Home-Based Directly Observed Treatment: Evidence from the United Republic of Tanzania. PLoS ONE, 2012, 7, e51828.	2.5	34
86	Evaluation of the Genotype® MTBDRplus assay as a tool for drug resistance surveys. International Journal of Tuberculosis and Lung Disease, 2011, 15, 959-965.	1.2	20
87	Coverage and yield of tuberculosis contact investigations in the Netherlands. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1630-1637.	1.2	20
88	Contact tracing in low-incidence tuberculosis settings. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1566-1566.	1.2	1
89	Health-seeking norms for tuberculosis symptoms in southern Angola: implications for behaviour change communications. International Journal of Tuberculosis and Lung Disease, 2011, 15, 943-948.	1.2	17
90	Incidence and Predictors of Mortality and the Effect of Tuberculosis Immune Reconstitution Inflammatory Syndrome in a Cohort of TB/HIV Patients Commencing Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 32-37.	2.1	61

#	ARTICLE	IF	CITATIONS
91	Projection of the number of patients with tuberculosis in the Netherlands in 2030. <i>European Journal of Public Health</i> , 2009, 19, 424-427.	0.3	12
92	Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study. <i>BMC Medicine</i> , 2009, 7, 80.	5.5	24
93	Implementation of a national anti-tuberculosis drug resistance survey in Tanzania. <i>BMC Public Health</i> , 2008, 8, 427.	2.9	9
94	Measuring tuberculosis burden, trends, and the impact of control programmes. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 233-243.	9.1	149
95	Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 26-34.	2.1	28
96	Prevalence of tuberculous infection and incidence of tuberculosis; a re-assessment of the Styblo rule. <i>Bulletin of the World Health Organization</i> , 2008, 86, 20-26.	3.3	71
97	Assessment of patient preference in allocation and observation of anti-tuberculosis medication in three districts in Tanzania. <i>Patient Preference and Adherence</i> , 2008, 2, 1-6.	1.8	9
98	Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: Response. <i>BMC Medical Research Methodology</i> , 2007, 7, 14.	3.1	0
99	Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. <i>HIV Medicine</i> , 2006, 7, 347-350.	2.2	13
100	Epstein-Barr Virus Infects B and Non-B Lymphocytes in HIV-1-Infected Children and Adolescents. <i>Journal of Infectious Diseases</i> , 2006, 194, 1323-1330.	4.0	28
101	Long-term Experience With Combination Antiretroviral Therapy That Contains Nelfinavir for up to 7 Years in a Pediatric Cohort. <i>Pediatrics</i> , 2006, 117, e528-e536.	2.1	37
102	Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens. <i>Aids</i> , 2005, 19, 1722-1723.	2.2	2
103	Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study. <i>HIV Clinical Trials</i> , 2005, 6, 254-261.	2.0	26
104	Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27 ⁺ T cells in HIV-1-infected children. <i>Aids</i> , 2005, 19, 1025-1034.	2.2	15
105	Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 296-300.	2.1	3
106	Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?. <i>Antiviral Therapy</i> , 2005, 10, 489-498.	1.0	135
107	Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study. <i>Antiviral Therapy</i> , 2005, 10, 145-155.	1.0	80
108	Lipid Profiles in HIV-1-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?. <i>Journal of Infectious Diseases</i> , 2004, 189, 1056-1074.	4.0	318

#	ARTICLE	IF	CITATIONS
109	Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1. PLoS Medicine, 2004, 1, e19.	8.4	220
110	Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. HIV Medicine, 2004, 5, 74-81.	2.2	31
111	Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet, The, 2004, 363, 1253-1263.	13.7	665
112	Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. Aids, 2004, 18, 1925-1931.	2.2	33
113	Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz. Antiviral Therapy, 2004, 9, 721-8.	1.0	10
114	Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz. Antiviral Therapy, 2004, 9, 721-728.	1.0	23
115	A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. Aids, 2003, 17, 987-999.	2.2	151
116	Use of Composite End Points to Measure Clinical Events. JAMA - Journal of the American Medical Association, 2003, 290, 1456-b-1457.	7.4	6
117	Highly Active Antiretroviral Therapy-Induced Lipodystrophy Has Minor Effects on Human Immunodeficiency Virus-Induced Changes in Lipolysis, but Normalizes Resting Energy Expenditure. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5066-5071.	3.6	33
118	Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. Aids, 2001, 15, 2407-2414.	2.2	212